These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 2111106

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Smear- and culture-negative pulmonary tuberculosis: four-month short-course chemotherapy.
    Dutt AK, Moers D, Stead WW.
    Am Rev Respir Dis; 1989 Apr; 139(4):867-70. PubMed ID: 2930066
    [Abstract] [Full Text] [Related]

  • 3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 4. Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin.
    Dutt AK, Moers D, Stead WW.
    Am Rev Respir Dis; 1992 Jun; 145(6):1429-32. PubMed ID: 1596014
    [Abstract] [Full Text] [Related]

  • 5. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [Abstract] [Full Text] [Related]

  • 6. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [Abstract] [Full Text] [Related]

  • 7. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM, Goldberg SV.
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [Abstract] [Full Text] [Related]

  • 8. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW, Snider DE, Farer LS.
    Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Smear-negative pulmonary tuberculosis.
    Dutt AK, Stead WW.
    Semin Respir Infect; 1994 Jun; 9(2):113-9. PubMed ID: 7973170
    [Abstract] [Full Text] [Related]

  • 11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee.
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [Abstract] [Full Text] [Related]

  • 12. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
    Am Rev Respir Dis; 1989 Apr; 139(4):871-6. PubMed ID: 2648911
    [Abstract] [Full Text] [Related]

  • 13. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
    Nowak D, Radenbach D, Magnussen H.
    Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
    [Abstract] [Full Text] [Related]

  • 14. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis?
    Wilkinson D, Bechan S, Connolly C, Standing E, Short GM.
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):52-5. PubMed ID: 9562111
    [Abstract] [Full Text] [Related]

  • 15. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ, Perng RP.
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [Abstract] [Full Text] [Related]

  • 16. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R, Borgdorff MW, Sticht-Groh V, Rieder HL, Kawuma HJ, Bretzel G, Rüsch-Gerdes S.
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [Abstract] [Full Text] [Related]

  • 17. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients.
    Dutt AK, Moers D, Stead WW.
    Am J Med; 1984 Aug; 77(2):233-42. PubMed ID: 6431810
    [Abstract] [Full Text] [Related]

  • 18. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 19. The results of 9-month isoniazid-rifampin therapy for pulmonary tuberculosis under program conditions in San Francisco.
    Slutkin G, Schecter GF, Hopewell PC.
    Am Rev Respir Dis; 1988 Dec; 138(6):1622-4. PubMed ID: 3144221
    [Abstract] [Full Text] [Related]

  • 20. Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy.
    Lancet; 1979 Jun 30; 1(8131):1361-3. PubMed ID: 87829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.